Cathay Biotech Inc. (SHA:688065)

China flag China · Delayed Price · Currency is CNY
54.68
+0.30 (0.55%)
At close: Feb 27, 2026
13.92%
Market Cap 39.41B
Revenue (ttm) 3.29B
Net Income (ttm) 594.46M
Shares Out 720.66M
EPS (ttm) 0.92
PE Ratio 59.59
Forward PE 60.09
Dividend 0.40 (0.73%)
Ex-Dividend Date Aug 1, 2025
Volume 3,334,203
Average Volume 5,428,414
Open 54.24
Previous Close 54.38
Day's Range 53.93 - 55.10
52-Week Range 43.07 - 64.50
Beta 0.76
RSI 49.43
Earnings Date Apr 24, 2026

About Cathay Biotech

Cathay Biotech Inc., together with its subsidiaries, engages in the research, development, production, and sale of bio-based materials in China and internationally. The company offers biological long-chain diacids, including sebacic acid and octadecanedioic acid; bio-based polyamides; and bio-based pentamethylene diamine under the TERRYL and ECOPENT brands. It also provides digital solutions for electrification, automation, and digitization for biological manufacturing. The company’s products are used in textiles, pharmaceuticals, perfumes, aut... [Read more]

Industry Chemicals
Sector Materials
Founded 2000
Employees 1,764
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688065
Full Company Profile

Financial Performance

In 2024, Cathay Biotech's revenue was 2.96 billion, an increase of 39.91% compared to the previous year's 2.11 billion. Earnings were 488.96 million, an increase of 33.41%.

Financial Statements

News

There is no news available yet.